Skip to main content
  • Book
  • © 2015

The Future of HIV-1 Therapeutics

Resistance Is Futile?

  • Highlights the identification and evaluation of antiretrovirals that may be less prone in selecting for HIV-1 resistance

  • Covers recent advances in the identification and function of small molecule inhibitors that target novel HIV-1 regulatory and structural components to disrupt replication and alter the state of viral latency

  • Offers up-to-date information for virologists, infectious disease specialists, and chemical biologists on HIV-1 antiretrovirals currently in use

  • Includes supplementary material: sn.pub/extras

Part of the book series: Current Topics in Microbiology and Immunology (CT MICROBIOLOGY, volume 389)

Buying options

eBook USD 119.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-18518-7
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book USD 159.99
Price excludes VAT (USA)
Hardcover Book USD 169.99
Price excludes VAT (USA)

This is a preview of subscription content, access via your institution.

Table of contents (9 chapters)

  1. Front Matter

    Pages i-x
  2. HIV Therapy—The State of ART

    • David Looney, Ariel Ma, Scott Johns
    Pages 1-29
  3. Nucleocapsid Protein: A Desirable Target for Future Therapies Against HIV-1

    • Mattia Mori, Lesia Kovalenko, Sébastien Lyonnais, Danny Antaki, Bruce E. Torbett, Maurizio Botta et al.
    Pages 53-92Open Access
  4. HIV-1 Integrase Multimerization as a Therapeutic Target

    • Lei Feng, Ross C. Larue, Alison Slaughter, Jacques J. Kessl, Mamuka Kvaratskhelia
    Pages 93-119
  5. Targeting HIV Transcription: The Quest for a Functional Cure

    • Guillaume Mousseau, Sonia Mediouni, Susana T. Valente
    Pages 121-145
  6. HIV-1 Gag: An Emerging Target for Antiretroviral Therapy

    • Philip R. Tedbury, Eric O. Freed
    Pages 171-201
  7. The Triple Threat of HIV-1 Protease Inhibitors

    • Marc Potempa, Sook-Kyung Lee, Richard Wolfenden, Ronald Swanstrom
    Pages 203-241
  8. Illustrations of the HIV Life Cycle

    • David S. Goodsell
    Pages 243-252
  9. Back Matter

    Pages 253-254

About this book

This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike.

Keywords

  • Fragment-based drug design
  • HIV Gag protein
  • HIV capsid
  • HIV integrase protein
  • HIV matrix
  • HIV nucleocapsid protein
  • HIV protease
  • HIV reverse transcriptase protein
  • HIV stem-loop
  • HIV transcription
  • HIV-1 antiretroviral treatment
  • HIV-1 drug resistance
  • HIV-1 illustrations
  • HIV-1 latency
  • High-throughput virtual screening
  • Human immunodeficiency virus
  • LEDGF/p75 protein
  • Rev protein
  • Structure-based drug design
  • Tat/TAR/P-TEFb complex
  • antibacterial drug resistance

Reviews

“The book does a fantastic job of addressing new approaches to inhibit HIV-1. … this is a useful book that can be used by researchers, HIV clinicians, and medicinal chemists interested in investigating new molecules for the treatment of HIV-1. It addresses novel areas that have no chemical entities that are FDA approved. There are no books that compete with this one.” (Christopher J. Destache, Doody's Book Reviews, September, 2015)

“This book includes 8 comprehensive, heavily referenced chapters on antiretroviral drug development. … a comprehensive, readable review of a subject that brings together 2 or more decades of molecular virology research and drug development. … the chapters in this book are likely to be, for the next several years, highly useful and popular starting points for learning about new areas in HIV drug development.” (Robert W. Shafer, Clinical Infectious Diseases, September, 2015)

Editors and Affiliations

  • Departments of Molecular and Experimental Medicine and Immunology and Microbial Science (MEM 131), The Scripps Research Institute, La Jolla, USA

    Bruce E. Torbett

  • Department of Integrative Structural and Computational Biology, and RCSB Protein Data Bank, The Scripps Research Institute, La Jolla, USA

    David S. Goodsell

  • Department of Pathology, University of California, San Diego, La Jolla, USA

    Douglas D. Richman

Bibliographic Information

Buying options

eBook USD 119.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-18518-7
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book USD 159.99
Price excludes VAT (USA)
Hardcover Book USD 169.99
Price excludes VAT (USA)